IBDEI027 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,479,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,479,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,480,0)
 ;;=C91.11^^2^21^14
 ;;^UTILITY(U,$J,358.3,480,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,480,1,3,0)
 ;;=3^Chronic lymphocytic leukemia of B-cell type in remission
 ;;^UTILITY(U,$J,358.3,480,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,480,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,481,0)
 ;;=C91.12^^2^21^15
 ;;^UTILITY(U,$J,358.3,481,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,481,1,3,0)
 ;;=3^Chronic lymphocytic leukemia of B-cell type in relapse
 ;;^UTILITY(U,$J,358.3,481,1,4,0)
 ;;=4^C91.12
 ;;^UTILITY(U,$J,358.3,481,2)
 ;;=^5001767
 ;;^UTILITY(U,$J,358.3,482,0)
 ;;=D47.1^^2^21^16
 ;;^UTILITY(U,$J,358.3,482,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,482,1,3,0)
 ;;=3^Chronic myeloproliferative disease
 ;;^UTILITY(U,$J,358.3,482,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,482,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,483,0)
 ;;=C94.42^^2^21^5
 ;;^UTILITY(U,$J,358.3,483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,483,1,3,0)
 ;;=3^Acute panmyelosis with myelofibrosis, in relapse
 ;;^UTILITY(U,$J,358.3,483,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,483,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,484,0)
 ;;=C94.41^^2^21^6
 ;;^UTILITY(U,$J,358.3,484,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,484,1,3,0)
 ;;=3^Acute panmyelosis with myelofibrosis, in remission
 ;;^UTILITY(U,$J,358.3,484,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,484,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,485,0)
 ;;=C94.40^^2^21^4
 ;;^UTILITY(U,$J,358.3,485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,485,1,3,0)
 ;;=3^Acute panmyelosis w myelofibrosis not achieve remission
 ;;^UTILITY(U,$J,358.3,485,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,485,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,486,0)
 ;;=D47.2^^2^21^48
 ;;^UTILITY(U,$J,358.3,486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,486,1,3,0)
 ;;=3^Monoclonal gammopathy
 ;;^UTILITY(U,$J,358.3,486,1,4,0)
 ;;=4^D47.2
 ;;^UTILITY(U,$J,358.3,486,2)
 ;;=^5002257
 ;;^UTILITY(U,$J,358.3,487,0)
 ;;=C88.0^^2^21^59
 ;;^UTILITY(U,$J,358.3,487,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,487,1,3,0)
 ;;=3^Waldenstrom macroglobulinemia
 ;;^UTILITY(U,$J,358.3,487,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,487,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,488,0)
 ;;=C77.0^^2^22^13
 ;;^UTILITY(U,$J,358.3,488,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,488,1,3,0)
 ;;=3^Secondary malignant neoplasm of nodes of head, face and neck
 ;;^UTILITY(U,$J,358.3,488,1,4,0)
 ;;=4^C77.0
 ;;^UTILITY(U,$J,358.3,488,2)
 ;;=^5001329
 ;;^UTILITY(U,$J,358.3,489,0)
 ;;=C77.1^^2^22^8
 ;;^UTILITY(U,$J,358.3,489,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,489,1,3,0)
 ;;=3^Secondary malignant neoplasm of intrathorac nodes
 ;;^UTILITY(U,$J,358.3,489,1,4,0)
 ;;=4^C77.1
 ;;^UTILITY(U,$J,358.3,489,2)
 ;;=^267315
 ;;^UTILITY(U,$J,358.3,490,0)
 ;;=C77.2^^2^22^7
 ;;^UTILITY(U,$J,358.3,490,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,490,1,3,0)
 ;;=3^Secondary malignant neoplasm of intra-abd nodes
 ;;^UTILITY(U,$J,358.3,490,1,4,0)
 ;;=4^C77.2
 ;;^UTILITY(U,$J,358.3,490,2)
 ;;=^267316
 ;;^UTILITY(U,$J,358.3,491,0)
 ;;=C77.3^^2^22^1
 ;;^UTILITY(U,$J,358.3,491,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,491,1,3,0)
 ;;=3^Secondary malignant neoplasm of axilla and upper limb nodes
 ;;^UTILITY(U,$J,358.3,491,1,4,0)
 ;;=4^C77.3
 ;;^UTILITY(U,$J,358.3,491,2)
 ;;=^5001330
 ;;^UTILITY(U,$J,358.3,492,0)
 ;;=C77.4^^2^22^6
 ;;^UTILITY(U,$J,358.3,492,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,492,1,3,0)
 ;;=3^Secondary malignant neoplasm of inguinal and lower limb nodes
 ;;
 ;;$END ROU IBDEI027
